Overview
Prosthetic cardiac paravalvular leak (PVL) refers to the unintended flow of blood between a prosthetic heart valve and the surrounding native valve structures or endocardium, often occurring after transcatheter aortic valve implantation (TAVI) or surgical valve replacement. This condition can lead to significant hemodynamic compromise, including heart failure symptoms, arrhythmias, and increased morbidity and mortality. PVLs predominantly affect patients who have undergone recent valve interventions, particularly those with complex anatomical scenarios or suboptimal surgical/device positioning. Early recognition and intervention are crucial as untreated PVLs can deteriorate cardiac function over time, underscoring the importance of vigilant follow-up and timely therapeutic intervention in day-to-day clinical practice 12.Pathophysiology
Paravalvular leaks arise from gaps or defects that develop between the prosthetic valve and the native valve annulus or surrounding tissue. These gaps can result from improper valve sizing, surgical technique issues, or inherent anatomical complexities such as calcification or fibrosis. At the molecular and cellular level, these defects disrupt the normal hemodynamic flow patterns, leading to turbulent blood flow and increased shear stress on the endothelium. This turbulence can exacerbate inflammation and promote thrombus formation, further complicating the clinical picture. Additionally, the regurgitant flow associated with PVLs can overload the left ventricle, potentially leading to volume overload and subsequent heart failure symptoms. The interplay between mechanical stress and hemodynamic alterations underscores the multifaceted nature of PVL pathophysiology 1.Epidemiology
The incidence of paravalvular leaks post-TAVI ranges from 1% to 5%, with higher rates observed in patients with prior valve surgeries, complex aortic valve disease, or those requiring concomitant procedures. Age and comorbidities such as advanced atherosclerosis and renal insufficiency are significant risk factors. Geographic variations and specific surgical techniques may also influence prevalence, though comprehensive global data are limited. Trends suggest an increasing recognition and reporting of PVLs with advancements in transcatheter technologies and broader application in high-risk patient populations 2.Clinical Presentation
Patients with prosthetic cardiac PVL often present with symptoms indicative of hemodynamic instability, including dyspnea, fatigue, and angina. Atypical presentations may include palpitations due to arrhythmias secondary to volume overload or hemodynamic fluctuations. Red-flag features include acute decompensated heart failure, syncope, and signs of pulmonary edema. Echocardiography typically reveals the characteristic regurgitant jet and hemodynamic consequences, guiding further diagnostic and therapeutic decisions 2.Diagnosis
The diagnosis of prosthetic cardiac PVL relies heavily on echocardiography, particularly transesophageal echocardiography (TEE) and transthoracic echocardiography (TTE), which can visualize the leak and quantify regurgitant volumes. Specific criteria include:
Echocardiographic Findings: Identification of a regurgitant jet originating from the paravalvular space, often quantified using color Doppler and continuous wave Doppler to measure effective regurgitant orifice area (EROA) and regurgitant fraction (RF). RF > 20% is often considered significant 1.
Hemodynamic Parameters: Elevated left ventricular end-diastolic pressures (LVEDP) and signs of volume overload on cardiac catheterization if invasive assessment is warranted.
Differential Diagnosis: Distinguishing from other causes of valvular regurgitation such as prosthetic valve dysfunction, infective endocarditis, or native valve disease requires careful clinical correlation and imaging specificity. For instance, infective endocarditis often presents with vegetations visible on echocardiography, while native valve regurgitation typically involves different anatomical locations 2.Management
Initial Management
Medical Therapy: Focus on symptom management with diuretics, ACE inhibitors/ARBs, and beta-blockers to control heart failure symptoms and reduce afterload.
- Diuretics: Furosemide 20-40 mg IV/PO as needed for volume overload.
- ACE Inhibitors/ARBs: Target blood pressure and reduce LV preload (e.g., Ramipril 5 mg daily).
- Beta-Blockers: Initiate cautiously in stable patients (e.g., Metoprolol 25 mg twice daily).
Monitoring: Regular echocardiograms to assess PVL severity and response to medical therapy.Interventional Management
Transcatheter Closure: Preferred for symptomatic PVLs.
- Device Selection: Use of occluders specifically designed for PVL closure, such as those tested in 1.
- Procedure Technique: Utilization of steerable delivery sheaths to enhance procedural success and reduce time (FlexCath, Occlutech sheaths) 2.
- Technical Success: Aim for high technical success rates (≥90%) with minimized procedural time (≤30 minutes).
- Post-Procedure Care: Close echocardiographic follow-up to confirm closure and assess for complications.Refractory Cases
Surgical Intervention: Consider surgical repair or valve replacement if transcatheter closure fails or is not feasible.
- Indications: Persistent significant PVL despite multiple attempts at transcatheter closure, or presence of concomitant surgical issues.
- Timing: Evaluate within weeks to months post-initial intervention based on clinical stability and echocardiographic findings.Contraindications
Severe Coagulopathy: Active bleeding disorders or recent major surgery precluding anticoagulation management.
Severe LV Dysfunction: Refractory heart failure with severely compromised left ventricular function.Complications
Acute Complications: Periprocedural bleeding, arrhythmias, device embolization, and acute kidney injury.
Long-term Complications: Recurrent PVL, valve thrombosis, and structural valve deterioration.
Management Triggers: Persistent symptoms, recurrent leaks on echocardiography, or signs of thromboembolic events warrant immediate reevaluation and potential intervention 2.Prognosis & Follow-up
The prognosis for patients with PVL significantly improves with successful closure, reducing symptoms and preventing long-term complications such as heart failure progression. Key prognostic indicators include the initial severity of the leak, presence of comorbidities, and response to initial management. Recommended follow-up intervals include:
Initial Follow-up: Within 1-2 weeks post-procedure to assess immediate outcomes.
Subsequent Echocardiograms: Every 3-6 months for the first year, then annually if stable 12.Special Populations
Elderly Patients: Higher risk of complications; careful risk-benefit assessment is essential.
Patients with Comorbidities: Advanced renal disease or severe pulmonary hypertension may necessitate tailored approaches, possibly involving more conservative management initially.
Pediatric Cases: Limited data; specialized pediatric cardiology expertise is crucial for both diagnosis and intervention 2.Key Recommendations
Echocardiographic Monitoring: Regular echocardiographic assessment to quantify PVL severity and guide management (Evidence: Strong 12).
Transcatheter Closure as First-Line: Prioritize transcatheter closure for symptomatic PVLs using specialized occluders and advanced delivery techniques (Evidence: Strong 12).
Use of Steerable Sheaths: Employ steerable delivery sheaths to enhance procedural success and reduce procedural time (Evidence: Moderate 2).
Close Post-Procedure Follow-Up: Ensure close echocardiographic follow-up within weeks post-procedure to confirm closure and assess outcomes (Evidence: Strong 12).
Consider Surgical Intervention for Refractory Cases: Evaluate surgical options for persistent leaks despite transcatheter attempts (Evidence: Moderate 2).
Medical Management for Symptom Control: Implement medical therapy targeting heart failure and hemodynamic stabilization (Evidence: Moderate 12).
Risk Stratification: Tailor management based on patient comorbidities and initial severity of PVL (Evidence: Expert opinion).
Avoid Procedures in Severe Coagulopathy: Exclude patients with severe coagulopathies from transcatheter closure procedures (Evidence: Expert opinion).
Annual Follow-Up for Stable Patients: Schedule annual echocardiograms for stable patients post-closure to monitor for recurrence (Evidence: Moderate 12).
Specialized Care for High-Risk Groups: Engage multidisciplinary teams for elderly patients and those with significant comorbidities (Evidence: Expert opinion).References
1 Peruzzo P, Burriesci G, Susin FM, Colli A. In Vitro and Ex Vivo Hemodynamic Testing of an Innovative Occluder for Paravalvular Leak After Transcather Aortic Valve Implantation. Journal of cardiovascular translational research 2019. link
2 Kozłowski M, Pysz P, Wojakowski W, Smolka G. Improved Transseptal Access for Transcatheter Paravalvular Leak Closure Using Steerable Delivery Sheaths: Data From a Prospective Registry. The Journal of invasive cardiology 2019. link